Patrick Arbuthnot

University of the Witwatersrand — South Africa

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index5.6kcitations162works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(79), Hepatitis B Virus Studies(69), Virus-based gene therapy research(43), Viral gastroenteritis research and epidemiology(31), CRISPR and Genetic Engineering(23)

Publications162 total

Structural mimics of SARS-CoV-2
Infection·2026Open Access
Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice
Viruses·2025· 2 citedOpen Access
Advancing the course of HIV genomics research in Africa
BMJ Global Health·2025Open Access
Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy
Pharmaceutics·2025Open Access
In Vitro Transcribed Artificial Primary MicroRNA for the Inhibition of Hepatitis B Virus Gene Expression in Cultured Cells
Microorganisms·2025Open Access
Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector
Virology Journal·2025· 6 citedOpen Access
Generating mRNA Encoding Anti-HBV Designer Epigenome Modifiers
Methods in molecular biology·2025
Bridging gene therapy and next-generation vaccine technologies
Gene Therapy·2024· 4 citedOpen Access
Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections
Pharmaceutics·2024· 2 citedOpen Access
In Vitro RNA Transcription
2024· 1 cited
Making genome editing a success story in Africa
Nature Biotechnology·2024· 11 citedOpen Access
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Microorganisms·2023· 3 citedOpen Access
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
The Lancet Infectious Diseases·2023· 39 citedOpen Access
Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines
Pharmaceutics·2023· 14 citedOpen Access
Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
Genes·2022· 10 citedOpen Access
Advancing mRNA technologies for therapies and vaccines: An African context
Frontiers in Immunology·2022· 20 citedOpen Access
Hepatitis B Virus Research in South Africa
Viruses·2022· 27 citedOpen Access
Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases
Gene Therapy·2022· 7 cited
Diversity of Dysregulated Long Non-Coding RNAs in HBV-Related Hepatocellular Carcinoma
Frontiers in Immunology·2022· 14 citedOpen Access
Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections
RNA technologies·2022
page 1 of 9Next →

Frequent Co-authors

Abdullah Ely(14), Michael C. Kew(14), Marc S. Weinberg(12), Carol Crowther(9), Mark A. Feitelson(9), Zhaorui Lian(8), Kristie Bloom(5), Sergio Carmona(5), Felix H. Salazar(5), Patricia L. Marion(5), Samantha Barichievy(4), Mohube Betty Maepa(4), Marcy Clayton(4), Buhle Moyo(4), Xianxing Li(4), Fiona T. van den Berg(3), Alexio Capovilla(3), Maluta Steven Mufamadi(3), Jingbo Pan(3), Jie Liu(3)